It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A clinical-stage biotech company developing novel antibody-based immuno-therapies generated by its differentiated discovery platform (Immune Repertoire Capture® (IRC))
- The IRC platform enables BCEL to discover novel therapies for cancer and other diseases by analyzing patients immune cells
- Lead asset ATRC-101= in P1b of development in multiple solid tumor cancers
- Several additional assets are in preclinical development for various diseases including COVID-19